

IWGDF Guidelines – Disclosure of interest form

Name: Robert Fitridge

Affiliation: University of Adelaide

Position: Professor of Vascular Surgery

IWGDF Working Group: PAD (Co-chair), Infection (member), member Editorial Board.



For the following items, please disclose any interest from the past five years that might be perceived by others as potentially influencing your judgment in any topic in the IWGDF Guideline(s) that you contribute to.

- Ancillary positions: NIL

- Personal financial interests: NIL

- Personal relations (this includes personal relations or relations via close family that might be perceived by others as potentially influencing your judgment):

NIL

- Externally funded research (this includes research funding awarded to you as project member, or to your department, for funding that might be perceived by others as potentially influencing your judgment). If yes, name the title/topic of the grant.

An Augmented Reality program to improve telemedicine delivery and wound research for people with chronic lower-extremity ulcers. R Fitridge CIA (Medical Research Futures Fund- National Critical Research Infrastructure Scheme, 2023-8)

Towards a culturally appropriate coordination, rehabilitation and secondary prevention model in primary care for Aboriginal people hospitalised with chronic disease. R Fitridge CIK (Medical Research Futures Fund- Indigenous Health Research)

Transforming diabetes assessment using artificial intelligence and photonics to measure skin health. R Fitridge CIA (University of Adelaide Healthy Societies FAME strategy Scale Grant, 2025-6)

Exercise for diabetes-related foot wounds: A randomised feasibility trial R Fitridge CIC. (Medical Research Futures Fund- Cardiovascular Disease and Diabetes Mechanisms 2025-7)

CYNATA. Therapeutics. A Randomised, Controlled, Phase 1 Study to Investigate Safety, Tolerability and Efficacy of CYP-006TK (mesenchymal stem cells) in Adults with Diabetic Foot Ulcers- R Fitridge CIA 2022-5. Departmental funding, no personal funding

Targeted microRNA Delivery to Reverse Diabetes-Impaired Angiogenesis R Fitridge CID (The Hospital Redearch Foundation, 2025-7)

Systematic lipid profiling and therapy optimisation in vascular surgical patients with very high-risk atherosclerotic disease. R Fitridge CIC (CALHN CEO Rapid Implementation Scheme, 2025-7)

Hybrid 3D-printed imaging catheter for more accurate cardiovascular disease detection. R Fitridge CID (NHMRC Development Grant 2023-5)

The Asialoglycoprotein Receptor 1 (ASGR1): a novel target for atherosclerosis. R Fitridge CIE (MRFF Cardiovascular Health Grant, 2022-6)

Development of a diagnostic platform for preventative wound management. R Fitridge CIC (NHMRC Ideas Grant, 2022-5)

- Other disclosures:

Nil.

When you have nothing to disclose, please state here:

Signature and date:

A handwritten signature in black ink, appearing to read 'R. Fitridge', written in a cursive style.

April 7, 2025.